vs
赛默飞世尔科技（TMO）与淡水河谷（VALE）财务数据对比。点击上方公司名可切换其他公司
赛默飞世尔科技的季度营收约是淡水河谷的1.3倍（$11.0B vs $8.8B），淡水河谷净利率更高（24.3% vs 15.0%，领先9.2%），赛默飞世尔科技同比增速更快（6.2% vs -11.3%）
赛默飞世尔科技是美国知名生命科学与临床研究企业，总部位于马萨诸塞州沃尔瑟姆，2006年由热电公司与飞世尔科技合并组建，为全球客户提供分析仪器、临床开发解决方案、特色诊断产品及实验室、制药、生物技术领域专业服务。
淡水河谷是巴西跨国金属矿业集团，也是巴西大型物流运营商之一，为全球最大的铁矿石和镍生产商。其产品线还覆盖锰、铁合金、铜、铝土矿、钾肥、高岭土、钴等，同时运营水电站及铁路、船舶、港口组成的庞大物流网络保障产品运输。
TMO vs VALE — 直观对比
营收规模更大
TMO
是对方的1.3倍
$8.8B
营收增速更快
TMO
高出17.4%
-11.3%
净利率更高
VALE
高出9.2%
15.0%
损益表 — Q1 FY2026 vs Q2 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $11.0B | $8.8B |
| 净利润 | $1.7B | $2.1B |
| 毛利率 | — | 30.9% |
| 营业利润率 | 16.9% | 22.8% |
| 净利率 | 15.0% | 24.3% |
| 营收同比 | 6.2% | -11.3% |
| 净利润同比 | 9.6% | -22.9% |
| 每股收益（稀释后） | $4.43 | $0.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收TMOVALE
| Q1 26 | $11.0B | — | ||
| Q4 25 | $12.2B | — | ||
| Q3 25 | $11.1B | — | ||
| Q2 25 | $10.9B | $8.8B | ||
| Q1 25 | $10.4B | — | ||
| Q4 24 | $11.4B | — | ||
| Q3 24 | $10.6B | — | ||
| Q2 24 | $10.5B | $9.9B |
净利润TMOVALE
| Q1 26 | $1.7B | — | ||
| Q4 25 | $2.0B | — | ||
| Q3 25 | $1.6B | — | ||
| Q2 25 | $1.6B | $2.1B | ||
| Q1 25 | $1.5B | — | ||
| Q4 24 | $1.8B | — | ||
| Q3 24 | $1.6B | — | ||
| Q2 24 | $1.5B | $2.8B |
毛利率TMOVALE
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 30.9% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 36.0% |
营业利润率TMOVALE
| Q1 26 | 16.9% | — | ||
| Q4 25 | 18.5% | — | ||
| Q3 25 | 17.5% | — | ||
| Q2 25 | 16.9% | 22.8% | ||
| Q1 25 | 16.6% | — | ||
| Q4 24 | 17.7% | — | ||
| Q3 24 | 17.3% | — | ||
| Q2 24 | 17.3% | 39.1% |
净利率TMOVALE
| Q1 26 | 15.0% | — | ||
| Q4 25 | 16.1% | — | ||
| Q3 25 | 14.5% | — | ||
| Q2 25 | 14.9% | 24.3% | ||
| Q1 25 | 14.6% | — | ||
| Q4 24 | 16.0% | — | ||
| Q3 24 | 15.4% | — | ||
| Q2 24 | 14.7% | 27.9% |
每股收益（稀释后）TMOVALE
| Q1 26 | $4.43 | — | ||
| Q4 25 | $5.21 | — | ||
| Q3 25 | $4.27 | — | ||
| Q2 25 | $4.28 | $0.50 | ||
| Q1 25 | $3.98 | — | ||
| Q4 24 | $4.78 | — | ||
| Q3 24 | $4.25 | — | ||
| Q2 24 | $4.04 | $0.65 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.3B | $5.5B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $51.9B | $40.5B |
| 总资产 | $113.3B | $90.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资TMOVALE
| Q1 26 | $3.3B | — | ||
| Q4 25 | $10.1B | — | ||
| Q3 25 | $3.5B | — | ||
| Q2 25 | $6.4B | $5.5B | ||
| Q1 25 | $5.9B | — | ||
| Q4 24 | $5.6B | — | ||
| Q3 24 | $6.6B | — | ||
| Q2 24 | $8.8B | $6.5B |
总债务TMOVALE
| Q1 26 | — | — | ||
| Q4 25 | $35.9B | — | ||
| Q3 25 | $31.9B | — | ||
| Q2 25 | $33.0B | — | ||
| Q1 25 | $31.4B | — | ||
| Q4 24 | $29.1B | — | ||
| Q3 24 | $31.2B | — | ||
| Q2 24 | $30.3B | — |
股东权益TMOVALE
| Q1 26 | $51.9B | — | ||
| Q4 25 | $53.4B | — | ||
| Q3 25 | $51.0B | — | ||
| Q2 25 | $50.5B | $40.5B | ||
| Q1 25 | $49.4B | — | ||
| Q4 24 | $49.6B | — | ||
| Q3 24 | $49.0B | — | ||
| Q2 24 | $47.4B | $38.4B |
总资产TMOVALE
| Q1 26 | $113.3B | — | ||
| Q4 25 | $110.3B | — | ||
| Q3 25 | $103.0B | — | ||
| Q2 25 | $101.2B | $90.4B | ||
| Q1 25 | $99.0B | — | ||
| Q4 24 | $97.3B | — | ||
| Q3 24 | $100.4B | — | ||
| Q2 24 | $98.5B | $86.6B |
负债/权益比TMOVALE
| Q1 26 | — | — | ||
| Q4 25 | 0.67× | — | ||
| Q3 25 | 0.62× | — | ||
| Q2 25 | 0.65× | — | ||
| Q1 25 | 0.64× | — | ||
| Q4 24 | 0.59× | — | ||
| Q3 24 | 0.64× | — | ||
| Q2 24 | 0.64× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.2B | — |
| 自由现金流经营现金流 - 资本支出 | $825.0M | — |
| 自由现金流率自由现金流/营收 | 7.5% | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | 0.72× | — |
| 过去12个月自由现金流最近4个季度 | $6.8B | — |
8季度趋势，按日历期对齐
经营现金流TMOVALE
| Q1 26 | $1.2B | — | ||
| Q4 25 | $3.5B | — | ||
| Q3 25 | $2.2B | — | ||
| Q2 25 | $1.4B | — | ||
| Q1 25 | $723.0M | — | ||
| Q4 24 | $3.3B | — | ||
| Q3 24 | $2.2B | — | ||
| Q2 24 | $2.0B | — |
自由现金流TMOVALE
| Q1 26 | $825.0M | — | ||
| Q4 25 | $3.0B | — | ||
| Q3 25 | $1.8B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $361.0M | — | ||
| Q4 24 | $2.8B | — | ||
| Q3 24 | $1.9B | — | ||
| Q2 24 | $1.7B | — |
自由现金流率TMOVALE
| Q1 26 | 7.5% | — | ||
| Q4 25 | 24.5% | — | ||
| Q3 25 | 16.5% | — | ||
| Q2 25 | 10.2% | — | ||
| Q1 25 | 3.5% | — | ||
| Q4 24 | 24.7% | — | ||
| Q3 24 | 17.9% | — | ||
| Q2 24 | 15.7% | — |
资本支出强度TMOVALE
| Q1 26 | — | — | ||
| Q4 25 | 3.8% | — | ||
| Q3 25 | 3.6% | — | ||
| Q2 25 | 2.7% | — | ||
| Q1 25 | 3.5% | — | ||
| Q4 24 | 4.2% | — | ||
| Q3 24 | 2.6% | — | ||
| Q2 24 | 2.9% | — |
现金转化率TMOVALE
| Q1 26 | 0.72× | — | ||
| Q4 25 | 1.75× | — | ||
| Q3 25 | 1.39× | — | ||
| Q2 25 | 0.87× | — | ||
| Q1 25 | 0.48× | — | ||
| Q4 24 | 1.80× | — | ||
| Q3 24 | 1.33× | — | ||
| Q2 24 | 1.27× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
TMO
| Laboratory Products and Biopharma Services | $6.0B | 55% |
| Life Sciences Solutions | $2.6B | 24% |
| Analytical Instruments | $1.7B | 16% |
| Specialty Diagnostics | $1.1B | 10% |
VALE
暂无分部数据
